{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:27:55Z","timestamp":1791937675571,"version":"4.3.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,20]]},"DOI":"10.7759\/cureus.82640","type":"journal-article","created":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T19:58:21Z","timestamp":1745179101000},"source":"Crossref","is-referenced-by-count":1,"title":["Methotrexate Shortages and Their Impact on Chronic Inflammatory Rheumatic Disease Management: Results From a National Survey of Moroccan Rheumatologists"],"prefix":"10.7759","author":[{"given":"Hind","family":"L'Heri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan","family":"Rkain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imane","family":"Bensaghir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Latifa","family":"Tahiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihane","family":"Belayachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Redouane","family":"Abouqal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajjaj-Hassouni","family":"Najia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadoua","family":"Allali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen JS","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RB, Bergstra SA, et al.. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023, 82:3-18. 10.1136\/ard-2022-223356","journal-title":"Ann Rheum Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec L","year":"2020","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A, et al.. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020, 79:700-12. 10.1136\/annrheumdis-2020-217159","journal-title":"Ann Rheum Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-018-0255-8","article-title":"Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting","volume":"16","author":"Ferrara G","year":"2018","unstructured":"Ferrara G, Mastrangelo G, Barone P, et al.. Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting. Pediatr Rheumatol Online J. 2018, 16:46. 10.1186\/s12969-018-0255-8","journal-title":"Pediatr Rheumatol Online J"},{"key":"ref4","article-title":"Methotrexate in rheumatoid arthritis: a quarter century of development","volume":"124","author":"Weinblatt ME","year":"2013","unstructured":"Weinblatt ME. Methotrexate in rheumatoid arthritis: a quarter century of development. Trans Am Clin Climatol Assoc. 2013, 124:16-25.","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0373-9","article-title":"Methotrexate and its mechanisms of action in inflammatory arthritis","volume":"16","author":"Cronstein BN","year":"2020","unstructured":"Cronstein BN, Aune TM. Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol. 2020, 16:145-54. 10.1038\/s41584-020-0373-9","journal-title":"Nat Rev Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211268","article-title":"Optimal methotrexate dose is associated with better clinical outcomes than non-optimal dose in daily practice: results from the ESPOIR early arthritis cohort","volume":"76","author":"Gaujoux-Viala C","year":"2017","unstructured":"Gaujoux-Viala C, Rincheval N, Dougados M, Combe B, Fautrel B. Optimal methotrexate dose is associated with better clinical outcomes than non-optimal dose in daily practice: results from the ESPOIR early arthritis cohort. Ann Rheum Dis. 2017, 76:2054-60. 10.1136\/annrheumdis-2017-211268","journal-title":"Ann Rheum Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221823","article-title":"Comparison of oral versus parenteral methotrexate in the treatment of rheumatoid arthritis: a meta-analysis","volume":"14","author":"Bujor AM","year":"2019","unstructured":"Bujor AM, Janjua S, LaValley MP, Duran J, Braun J, Felson DT. Comparison of oral versus parenteral methotrexate in the treatment of rheumatoid arthritis: a meta-analysis. PLoS One. 2019, 14:e0221823. 10.1371\/journal.pone.0221823","journal-title":"PLoS One"},{"key":"ref8","article-title":"Subcutaneous administration of methotrexate with a prefilled autoinjector pen results in a higher relative bioavailability compared with oral administration of methotrexate","volume":"32","author":"Pichlmeier U","year":"2014","unstructured":"Pichlmeier U, Heuer KU. Subcutaneous administration of methotrexate with a prefilled autoinjector pen results in a higher relative bioavailability compared with oral administration of methotrexate. Clin Exp Rheumatol. 2014, 32:563-71.","journal-title":"Clin Exp Rheumatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2015.11.004","article-title":"Subcutaneous administration of methotrexate at high doses makes a better performance in the treatment of rheumatoid arthritis compared with oral administration of methotrexate: a systematic review and meta-analysis","volume":"45","author":"Li D","year":"2016","unstructured":"Li D, Yang Z, Kang P, Xie X. Subcutaneous administration of methotrexate at high doses makes a better performance in the treatment of rheumatoid arthritis compared with oral administration of methotrexate: a systematic review and meta-analysis. Semin Arthritis Rheum. 2016, 45:656-62. 10.1016\/j.semarthrit.2015.11.004","journal-title":"Semin Arthritis Rheum"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.reumae.2020.11.006","article-title":"Use of parenteral methotrexate in rheumatic diseases: a systematic review","volume":"18","author":"Ot\u00f3n T","year":"2022","unstructured":"Ot\u00f3n T, Carmona L, Loza E, Rosario MP, Andreu JL. Use of parenteral methotrexate in rheumatic diseases: a systematic review. Reumatol Clin (Engl Ed). 2022, 18:207-26. 10.1016\/j.reumae.2020.11.006","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roac156","article-title":"Subcutaneous injection of methotrexate: advantages in the treatment of rheumatoid arthritis","volume":"33","author":"Tanaka Y","year":"2023","unstructured":"Tanaka Y. Subcutaneous injection of methotrexate: advantages in the treatment of rheumatoid arthritis. Mod Rheumatol. 2023, 33:633-9. 10.1093\/mr\/roac156","journal-title":"Mod Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2011.02.019","article-title":"Remission in early rheumatoid arthritis treated with conventional DMARDs. Results of a two-year follow-up study of El Ayachi Moroccan cohort","volume":"79","author":"Benbouazza K","year":"2012","unstructured":"Benbouazza K, Rkain H, Benchekroun B, et al.. Remission in early rheumatoid arthritis treated with conventional DMARDs. Results of a two-year follow-up study of El Ayachi Moroccan cohort. Joint Bone Spine. 2012, 79:43-6. 10.1016\/j.jbspin.2011.02.019","journal-title":"Joint Bone Spine"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2022.03.005","article-title":"Treatment guidelines in rheumatoid arthritis","volume":"48","author":"Singh JA","year":"2022","unstructured":"Singh JA. Treatment guidelines in rheumatoid arthritis. Rheum Dis Clin North Am. 2022, 48:679-89. 10.1016\/j.rdc.2022.03.005","journal-title":"Rheum Dis Clin North Am"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-015-0831-8","article-title":"Determinants of adherence to disease modifying anti-rheumatic drugs in White British and South Asian patients with rheumatoid arthritis: a cross sectional study","volume":"16","author":"Kumar K","year":"2015","unstructured":"Kumar K, Raza K, Nightingale P, Horne R, Chapman S, Greenfield S, Gill P. Determinants of adherence to disease modifying anti-rheumatic drugs in White British and South Asian patients with rheumatoid arthritis: a cross sectional study. BMC Musculoskelet Disord. 2015, 16:396. 10.1186\/s12891-015-0831-8","journal-title":"BMC Musculoskelet Disord"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-016-1289-z","article-title":"Barriers and facilitators to disease-modifying antirheumatic drug use in patients with inflammatory rheumatic diseases: a qualitative theory-based study","volume":"17","author":"Voshaar M","year":"2016","unstructured":"Voshaar M, Vriezekolk J, van Dulmen S, van den Bemt B, van de Laar M. Barriers and facilitators to disease-modifying antirheumatic drug use in patients with inflammatory rheumatic diseases: a qualitative theory-based study. BMC Musculoskelet Disord. 2016, 17:442. 10.1186\/s12891-016-1289-z","journal-title":"BMC Musculoskelet Disord"},{"key":"ref16","unstructured":"Methotrexate Shortage. Why It\u2019s Happening & Potential Solutions. (2023). Accessed: July 2023: https:\/\/www.the-rheumatologist.org\/article\/methotrexate-shortage-why-its-happening-potential-solutions\/."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen JS","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RB, Bijlsma JW, et al.. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020, 79:685-99. 10.1136\/annrheumdis-2019-216655","journal-title":"Ann Rheum Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha D","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, et al.. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010, 62:2569-81. 10.1002\/art.27584","journal-title":"Arthritis Rheum"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2018.09.027","article-title":"Side effects of methotrexate therapy for rheumatoid arthritis: a\u00a0systematic review","volume":"158","author":"Wang W","year":"2018","unstructured":"Wang W, Zhou H, Liu L. Side effects of methotrexate therapy for rheumatoid arthritis: a\u00a0systematic review. Eur J Med Chem. 2018, 158:502-16. 10.1016\/j.ejmech.2018.09.027","journal-title":"Eur J Med Chem"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000951.pub2","article-title":"Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis","volume":"2013","author":"Shea B","year":"2013","unstructured":"Shea B, Swinden MV, Tanjong Ghogomu E, et al.. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev. 2013, 2013:CD000951. 10.1002\/14651858.CD000951.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-012-0685-y","article-title":"The time course of gastric methotrexate intolerance in patients with rheumatoid arthritis and psoriatic arthritis","volume":"23","author":"Dalkilic E","year":"2013","unstructured":"Dalkilic E, Sahbazlar M, Gullulu M, et al.. The time course of gastric methotrexate intolerance in patients with rheumatoid arthritis and psoriatic arthritis. Mod Rheumatol. 2013, 23:525-8. 10.1007\/s10165-012-0685-y","journal-title":"Mod Rheumatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/art.23144","article-title":"Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial","volume":"58","author":"Braun J","year":"2008","unstructured":"Braun J, K\u00e4stner P, Flaxenberg P, et al.. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008, 58:73-81. 10.1002\/art.23144","journal-title":"Arthritis Rheum"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-016-1254-x","article-title":"Patient's experience with subcutaneous and oral methotrexate for the treatment of rheumatoid arthritis","volume":"17","author":"Curtis JR","year":"2016","unstructured":"Curtis JR, Xie F, Mackey D, et al.. Patient's experience with subcutaneous and oral methotrexate for the treatment of rheumatoid arthritis. BMC Musculoskelet Disord. 2016, 17:405. 10.1186\/s12891-016-1254-x","journal-title":"BMC Musculoskelet Disord"},{"key":"ref24","article-title":"Comparing healthcare costs associated with oral and subcutaneous methotrexate or biologic therapy for rheumatoid arthritis in the United States","volume":"10","author":"Lee J","year":"2017","unstructured":"Lee J, Pelkey R, Gubitosa J, Henrick MF, Ganz ML. Comparing healthcare costs associated with oral and subcutaneous methotrexate or biologic therapy for rheumatoid arthritis in the United States. Am Health Drug Benefits. 2017, 10:42-9.","journal-title":"Am Health Drug Benefits"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.24398\/A.458.2022","article-title":"[Actualisation des recommandations de la Soci\u00e9t\u00e9 Marocaine de Rhumatologie pour la prise en charge de la polyarthrite rhumato\u00efde]","author":"Ghozlani I","year":"2022","unstructured":"Ghozlani I, Kherrab A, Mougui A, et al.. [Actualisation des recommandations de la Soci\u00e9t\u00e9 Marocaine de Rhumatologie pour la prise en charge de la polyarthrite rhumato\u00efde]. Rev Maroc Rhumatol. 2022, 10.24398\/A.458.2022","journal-title":"Rev Maroc Rhumatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-020-04762-7","article-title":"One-year direct costs of biological therapy in rheumatoid arthritis and its predictive factors: data from the Moroccan RBSMR registry","volume":"41","author":"Fellous S","year":"2021","unstructured":"Fellous S, Rkain H, Ahid S, et al.. One-year direct costs of biological therapy in rheumatoid arthritis and its predictive factors: data from the Moroccan RBSMR registry. Rheumatol Int. 2021, 41:787-93. 10.1007\/s00296-020-04762-7","journal-title":"Rheumatol Int"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/357083-methotrexate-shortages-and-their-impact-on-chronic-inflammatory-rheumatic-disease-management-results-from-a-national-survey-of-moroccan-rheumatologists","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T19:58:23Z","timestamp":1745179103000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/357083-methotrexate-shortages-and-their-impact-on-chronic-inflammatory-rheumatic-disease-management-results-from-a-national-survey-of-moroccan-rheumatologists"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,20]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.82640","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,20]]}}}